Obseva (NASDAQ:OBSV) received a $44.00 target price from research analysts at HC Wainwright in a note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 247.83% from the company’s current price.

A number of other equities research analysts have also issued reports on OBSV. Leerink Swann began coverage on shares of Obseva in a report on Wednesday, August 15th. They issued an “outperform” rating and a $25.00 price target on the stock. Wedbush began coverage on shares of Obseva in a report on Monday, August 6th. They issued an “outperform” rating and a $34.00 price target on the stock. Zacks Investment Research raised shares of Obseva from a “sell” rating to a “buy” rating and set a $15.00 price target on the stock in a report on Wednesday, August 1st. BMO Capital Markets raised their price target on shares of Obseva from $23.00 to $31.00 and gave the stock an “outperform” rating in a report on Monday, June 18th. Finally, ValuEngine raised shares of Obseva from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Eight investment analysts have rated the stock with a buy rating, Obseva has an average rating of “Buy” and an average price target of $27.86.

Shares of Obseva stock opened at $12.65 on Wednesday. The firm has a market capitalization of $447.07 million, a price-to-earnings ratio of -5.62 and a beta of 2.13. Obseva has a 12-month low of $6.15 and a 12-month high of $20.35.

Obseva (NASDAQ:OBSV) last announced its quarterly earnings results on Wednesday, August 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.05. equities analysts expect that Obseva will post -1.98 earnings per share for the current year.

Large investors have recently bought and sold shares of the company. US Bancorp DE purchased a new stake in shares of Obseva in the 2nd quarter worth about $197,000. Tiverton Asset Management LLC purchased a new stake in shares of Obseva in the 2nd quarter worth about $224,000. DRW Securities LLC lifted its position in shares of Obseva by 39.7% in the 1st quarter. DRW Securities LLC now owns 21,812 shares of the company’s stock worth $294,000 after purchasing an additional 6,202 shares during the period. Jane Street Group LLC purchased a new stake in shares of Obseva in the 2nd quarter worth about $349,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Obseva in the 2nd quarter worth about $519,000. 68.26% of the stock is owned by hedge funds and other institutional investors.

About Obseva

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Featured Article: How Do I Invest in Dividend Stocks

Analyst Recommendations for Obseva (NASDAQ:OBSV)

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.